Tue Sep 17 05:43:35 UTC 2024: ## ANI Pharmaceuticals Beats Earnings Expectations, Analysts Remain Bullish

**ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)** exceeded analysts’ expectations in the third quarter of 2024, reporting earnings per share (EPS) of $1.02, surpassing the consensus estimate of $0.95. The company also saw revenue growth of 18.5% year-over-year, reaching $138 million, exceeding the expected $129.09 million.

Despite this positive performance, some analysts have adjusted their price targets for ANI Pharmaceuticals. **Capital One Financial** remains optimistic, forecasting EPS of $3.45 for the full year 2024, while **Truist Financial** lowered their price objective from $80.00 to $60.00, citing concerns about the company’s future performance.

However, **HC Wainwright** remains bullish, maintaining a “buy” rating with a price objective of $94.00. Overall, analysts currently maintain a “Moderate Buy” rating for ANI Pharmaceuticals with an average price target of $77.75.

**Insider trading activity** at ANI Pharmaceuticals has been mixed, with COO Muthusamy Shanmugam selling 14,257 shares and SVP Chad Gassert selling 20,000 shares. However, institutional investors continue to show confidence in the company, with several hedge funds increasing their holdings in recent months.

ANI Pharmaceuticals remains focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals across the United States and Canada. The company’s diverse product portfolio and strong financial performance suggest a positive outlook for the future.

Read More